Citius Pharmaceuticals Inc (CTXR) Implied Volatility Current

Tracking CTXR implied volatility helps you identify when options premiums on Citius Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Citius Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when CTXR IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Citius Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For CTXR, tracking metrics like CTXR IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on CTXR signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where CTXR implied volatility sits today versus where it has been. Our scanner ranks Citius Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in CTXR IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Citius Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.